FFO
TAK icon

Fortitude Family Office’s Takeda Pharmaceutical TAK Stock Holding History

Fortitude Family Office’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-243
Closed -$3.38K – 1054
2024
Q1 		$3.38K Hold
243
– – ﹤0.01% 727
2023
Q4 		$3.47K Buy
+243
New +$3.45K ﹤0.01% 790

Other funds holding TAK

GAM
Groupama Asset Management Paris, France $6.85B AUM 43.37% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Fortitude Family Office's TAK Position: Q2 2024 in Review

Fortitude Family Office sold out of Takeda Pharmaceutical (TAK) in Q2 2024, closing a stake of 243 shares — an estimated $3.38K sold.

Fortitude Family Office first reported a position in TAK in Q4 2023 and held it in 2 quarters. The position peaked at $3.47K in Q4 2023. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2024.

  • Fortitude Family Office reported no remaining Takeda Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Fortitude Family Office sold 243 Takeda Pharmaceutical shares in Q2 2024, an estimated $3.38K.
  • Fortitude Family Office first reported a position in Takeda Pharmaceutical in Q4 2023 and held it in 2 quarters.
  • Fortitude Family Office's Takeda Pharmaceutical position peaked at $3.47K in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2024.

Based on Fortitude Family Office's 13F filing for Q2 2024, filed 10 Jul 2024.